What is Inscripta?
Headquartered in Boulder, Colorado, Inscripta is pioneering the development of the world's first benchtop platform for scalable digital genome engineering. By integrating hardware, consumables, software, and assays into a unified, fully automated workflow, the company enables researchers to perform massively parallel, trackable single-cell editing. This technological leap addresses critical bottlenecks in synthetic biology, positioning Inscripta as a vital infrastructure provider for the next generation of life sciences innovation. The company's market position is defined by its commitment to democratizing access to high-throughput genetic modification, moving beyond traditional, labor-intensive laboratory methods.
How much funding has Inscripta raised?
Inscripta has raised a total of $417.5M across 6 funding rounds:
Series A
$6M
Series B
$23M
Series C
$55.5M
Series D
$125M
Unspecified
$58M
Series E
$150M
Series A (2016): $6M, investors not publicly disclosed
Series B (2017): $23M led by Spruce/MLS, Foresite Capital, Paladin Capital Group, Venrock Healthcare Partners, and NanoDimension
Series C (2018): $55.5M supported by Paladin Capital Group, Mérieux Développement, and Venrock
Series D (2019): $125M featuring NanoDimension, Oak HC/FT, JS Capital Management LLC, Foresite, Paladin Capital Group, MLS Capital, Mérieux Développement, and Venrock
Unspecified (2020): $58M, investors not publicly disclosed
Series E (2021): $150M with participation from Fidelity Management Corporation and T. Rowe Price
Key Investors in Inscripta
T. Rowe Price
A global investment management firm founded in 1937 that provides equity and fixed income solutions to institutional and individual investors worldwide.
Oak HC/FT
A premier venture growth-equity fund focused on driving transformation within the healthcare information and financial services technology sectors.
Paladin Capital Group
A global multi-stage investment firm that combines deep sector expertise with operational acumen to accelerate growth for companies across diverse industries.
What's next for Inscripta?
The recent strategic investment provides Inscripta with the necessary runway to accelerate the commercial deployment of its genome engineering ecosystem. As the company transitions from development to widespread market adoption, the focus will likely shift toward expanding its software capabilities and broadening the application scope of its CRISPR-based instruments. By leveraging its robust balance sheet, Inscripta is well-positioned to scale its operations, enhance its intellectual property portfolio, and maintain its competitive edge in the rapidly evolving field of digital biology. Future growth will be predicated on the company's ability to integrate its platform into diverse research environments, from academic institutions to large-scale industrial biotechnology firms.
See full Inscripta company page
